The effect of a low molecular weight heparin on coagulation parameters in healthy cats

Canadian Journal of Veterinary Research

Volumn 73, Issue 2, 2009, Pages 132-136

  Vargo, Cheryl L ^a,b   Taylor, Susan M ^a   Carr, Anthony ^a   Jackson, Marion L ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Veterinary Specialty Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; CONTROLLED STUDY; EXPERIMENTAL CAT; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; CATS; DALTEPARIN; FACTOR XA; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; STATISTICS, NONPARAMETRIC;

EID: 66549104875     PISSN: 08309000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rush JE, Freeman LM, Fenollosa NK, et al. Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990-1999). J Am Vet Med Assoc 2002;220:202-207.
2. Rodriguez DB, Harpster N. Aortic thromboembolism associated with feline hypertrophic cardiomyopathy. Compen Contin Educ Pract Vet 2002;24:478-482.
3. Smith CE, Rozanski EA, Freeman LM, et al. Use of low molecular weight heparin in cats: 57 cases (1999-2003). J Am Vet Med Assoc 2004;225:1237-1241.
4. Fareed J, Hoppensteadt, DA, Bick RL. An update on heparins at the beginning of the new millennium. Seminars in Thrombosis and Hemostasis 2000;26:5-21.
5. Weitz JI. Low molecular weight heparins. N Engl J Med 1997;337:688-697.
6. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998;114:489S-510S. (Pubitemid 28535777)
7. Dunn M. Use of low molecular weight heparins. Proc. 22nd ACVIM Minneapolis, Minnesota, USA 2004:528-529.
8. Dunn M, Charland V, Thorneloe C. The use of a low molecular weight heparin in 6 dogs (abstract). J Vet Int Med 2004;18:389.
9. Mischke R, Grebe S, Jacobs C, Kietzmann M. Amidolytic heparin therapy and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs. Am J Vet Res 2001;62:595-598. (Pubitemid 32245045)
10. Grebe S, Jacobs C, Kietzmann M, Mischke R. Pharmakokinetik des niedermolekularen Heparins Fragmin D beim Hund. Berl. Munch Tierarztl Wschr 2000;113:103-107. (Pubitemid 30186260)
11. Jacobs C, Grebe S, Kietzmann M, Mischke R. Pharmakokinetik des unfraktionierten Heparins Liquemin beim Hund nach intravenoser und subkutaner Injektion basierend auf der Heparin-aktivitat Dtsch Tierarztl Wschr 1999;106:478-481.
12. Hellebrekers LJ, Slappendel RJ, van den Brom WE. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog. Am J Vet Res 1985;46:1460-1462. (Pubitemid 15063474)
13. Mischke RH, Schuttert C, Grebe S. Anticoagulant effects of repeated subcutaneous injections of high doses of unfractioned heparin in healthy dogs. Am J Vet Res 2001;62:1887-1891. (Pubitemid 33130535)
14. Mischke R, Grebe S. The correlation between anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin. Res Vet Sci 2000;69:241-247. (Pubitemid 32109481)
15. Defrancesco TC, Moore RR, Atkins CE, et al. Comparison of dalteparin and warfarin in the long-term management of feline arterial thromboembolism (abstract). J Vet Int Med 2003;17:448-449.
16. Goodman JS, Rozanski EA, Brown D, et al. The effects of low-molecular-weight heparin on hematologic and coagulation parameters in normal cats (abstract). J Vet Intern Med 1999;13:268.
17. Alwood AJ, Downend AB, Brooks MB, et al. Anticoagulant effects of low molecular weight heparin in healthy cats (abstract). Journal of Emergency and Critical Care 2004;14:S1-S17.
18. Smith SA, Lewis DC, Kellerman DL. Adjustments of intermittent subcutaneous heparin therapy based on chromogenic heparin assay in 9 cats with thromboembolism (abstract). Proc. 16th ACVIM forum 1998: abstract #9.
19. Hackner SG. Pulmonary thromboembolism. In: King LG, ed. Textbook of Respiratory Disease in Dogs and Cats. St. Louis, Missouri: Elsevier, 2004:526-540.
20. Leizorovicz A, Bara L, Samama MM, Haugh MC. Factor Xa inhibition: Correlation between the plasma levels of Anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis 1993;23:89-98. (Pubitemid 23116280)
21. Bay JD, Scott MA, Hans JE. Reference values for activated coagulation time in cats. Am J Vet Res 2000;61:750-753.
22. Alwood AJ, Downend AB, Brooks MB, et al. Anticoagulant effects of low-molecular-weight heparins in healthy cats. J Vet Intern Med 2007;21:378-387. (Pubitemid 46814182)